A recent meta-analysis of randomized controlled trials (RCTs), including AMPLITUDE-O, examining six GLP-1 receptor agonists (lixisenatide, liraglutide, subcutaneous semaglutide, exenatide, dulaglutide, and efpeglenatide) reported a 21% reduction in a composite kidney outcome (macroalbuminuria, doubling of serum creatinine or 40% eGFR decline, RRT, or death from kidney disease), corresponding to a number needed to treat of 47 [73]
These resolve within 24 to 48 hours for most researchers and can be minimized with the dilution technique mentioned in the dosing section
[DOI] [PMC free article] [PubMed] [Google Scholar] 106.Rainero I., Limone P., Ferrero M., Valfr W., Pelissetto C., Rubino E., Gentile S., Lo Giudice R., Pinessi L
According to recent research published in medical journals, retatrutide achieved up to 24.2% mean weight loss after 48 weeks in individuals with obesity
SingleCare can help you save close to $622 per month on Zepbound
Cardio and protein matter, but if we had to prioritize, lifting weights changes physiology in ways that resistance training uniquely supports especially when someone is using appetite-suppressing medications or is at risk for sarcopenia
